This presentation is delivered by Aerovate Therapeutics, an industry partner of PHA Europe. They are in the process of developing a new PH medication that is based on a well-established component and is administered as an inhaled drug. During the presentation, Aerovate provides details about their drug and discusses their completed phase 2 trials as well as the forthcoming phase 3 trial. The presentation concludes with an engaging Q&A session lasting almost 20 minutes.